Related Experiment Video

Updated: Jun 17, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Recent advances in cardiology

Ian A Menown1, James A Shand

  • 1Craigavon Cardiac Centre, Southern Trust, Northern Ireland, BT63 5QQ, UK. ian.menown@southerntrust.hscni.net

Future Cardiology
|December 18, 2009
PubMed

Insights

Cardiology trials in 2009 introduced new findings in anticoagulation, antiplatelet therapy, and percutaneous coronary interventions. These advancements impact the management of coronary disease and heart failure.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • 2009 saw significant advancements in cardiovascular medicine.
  • Numerous major clinical trials were published, impacting treatment guidelines.

Purpose of the Study:

  • To summarize and contextualize key findings from 2009 cardiology trials.
  • To provide clinical insights into new therapeutic strategies.

Main Methods:

  • Review and synthesis of major cardiology trial data presented or published in 2009.
  • Categorization of findings by therapeutic area: anticoagulation, antiplatelet therapy, percutaneous coronary management, medical therapy, and heart failure management.

Main Results:

  • New anticoagulants like dabigatran showed promise.
  • Novel antiplatelet agents (ticagrelor, prasugrel) alongside existing ones (clopidogrel, aspirin) were evaluated.
  • Percutaneous coronary interventions explored thrombectomy, multivessel/left main disease, and biodegradable polymers.
  • Medical therapies including ivabradine and rosuvastatin were assessed.
  • Heart failure management strategies involving beta-blockers, atrial fibrillation, and resynchronization therapy were updated.

Conclusions:

  • The 2009 trial data significantly advanced the understanding and treatment of cardiovascular diseases.
  • Clinicians must integrate these new findings into patient care for optimal outcomes.
  • Ongoing research continues to refine cardiovascular disease management.

More Related Videos

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Introduction Cardiac Emergencies01:30

Introduction Cardiac Emergencies

Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...